Search Share Prices
Sareum Holdings to present SRA737 results in Chicago
Specialist cancer drug discovery and development company Sareum Holdings announced on Thursday that late-breaking preclinical results for SRA737 have been accepted for presentation in a poster at the American Association of Cancer Research Annual Meeting 2018 being held in Chicago from 14-18 April.
The AIM-traded firm said the data demonstrated that SRA737 has anti-tumour activity as a monotherapy in both CCNE1-driven cancer models and in cancer models resistant to poly ADP-ribose (PARP) inhibitor therapy, thereby warranting further investigation in human clinical studies.
"Sierra Oncology recently announced that its ongoing Phase 1/2 monotherapy trial for SRA737 was being expanded to include an additional genetically-defined cohort, targeting enrolment of 20 patients with CCNE1-driven ovarian cancer," the Sareum board said in its statement.
"Approximately 20% of high grade serous ovarian cancers have an amplification of the CCNE1 gene, which is also prevalent across several other tumour types under evaluation in Sierra Oncology's ongoing clinical development programme, including non-small cell lung, colorectal, bladder and cervical cancer."
Sierra Oncology also recently announced it was planning to start a Phase 1b/2 combination trial in the UK of SRA737 with the PARP inhibitor niraparib in patients with prostate cancer, expected in the fourth quarter of 2018.